Archive for 2010

Moisture Analysis

Freelance Sarah Webster describes how Biopharma Technology is using laser-based headspace moisture analysis for rapid and non-destructive moisture determination of freeze-dried pharmaceutical products. http://www.manufacturingchemist.com/technical/article_page/Moisture_analysis/55599


Click here for reuse options!
Copyright 2010 Biotechblog

Globalization in the pharmaceutical industry: Where are drugs invented?

I’ve just had a paper published in Nature Reviews Drug Discovery, using data from DrugPatentWatch to profile the locations of drug invention for the past decade. The location of drug development is important for two reasons. Firstly, it is important to track the global spread of innovation. Much late stage drug development (e.g. clinical trials) and […]


Click here for reuse options!
Copyright 2010 Biotechblog

Globalization of Pharmaceutical Innovation: Who is leading in drug development?

DrugPatentWatch.com publishes research paper profiling trends in global distribution of pharmaceutical innovation


Click here for reuse options!
Copyright 2010 Biotechblog

Bad boards of directors kill more companies than bad management…

A side-comment at the Mid Atlantic Biotech conference really got me thinking. One of the panelists mentioned as an aside that she thought that more companies failed due to bad boards than due to bad management (she preferred not to be named). The board of directors is more than a set of advisors to company […]


Click here for reuse options!
Copyright 2010 Biotechblog

Next DCbiotech meeting: Tuesday November 2nd

The next DCbiotech meeting will be at the Marriott Renaissance Washington DC Downtown Hotel on November 2nd  2010. The hotel is at 999 Ninth Street NW, and we’ll be meeting in the Mixx bar from 6:30-8:30pm. To facilitate finding the group, you may want to check out my photo on the about page. Where: Mixx […]


Click here for reuse options!
Copyright 2010 Biotechblog

Bringing Better Medicines to Market Faster, an Interview with Expert John Avellanet

Positive reviews of the book, Get to Market Now! Turn FDA Compliance into a Competitive Edge in the Era of Personalized Medicine, have been appearing since the book’s publication earlier this year.  The BiotechBlog sat down with author John Avellanet for a discussion of the book’s appeal. BB:   Why do you think the book is […]


Click here for reuse options!
Copyright 2010 Biotechblog

Drug Patent Expirations in October 2010

Drug Patent Expirations in October 2010 *Drugs may be covered by multiple patents Tradename Applicant Generic Name Patent Number Patent Expiration ORGARAN Organon Usa Inc danaparoid sodium 5,164,377 Oct 3, 2010 MIRAPEX ER Boehringer Ingelheim pramipexole dihydrochloride 4,886,812 Oct 8, 2010 MIRAPEX Boehringer Ingelheim pramipexole dihydrochloride 4,886,812 Oct 8, 2010 CLIMARA PRO Bayer Hlthcare estradiol; […]


Click here for reuse options!
Copyright 2010 Biotechblog

Developing a biotechnology cluster in Japan

The panel on applying Design Thinking to biotechnology was well received, and I look forward to writing up my observations. I’m now in Japan for a workshop on developing a biotechnology cluster. The U.S. biotechnology industry – the largest in the world – was basically developed with  strong  support from Japanese pharmaceutical and brewing companies. […]


Click here for reuse options!
Copyright 2010 Biotechblog

Biotechnology and a Better World by Design

I will be moderating a panel on the roles of biotechnology in development at the upcoming A Better World by Design conference at Brown University. The theme of the panel will be the promise and challenges of implementing biotechnology advances for public benefit, with a focus on topics such as disease prevention, agricultural improvements, and […]


Click here for reuse options!
Copyright 2010 Biotechblog

Medicine for Tomorrow: An Article on Pharmaceutical Research and Development by Nobel Prize-Winning Economist Joseph Stiglitz

As stringent new budgets have led to pharmaceutical companies cutting back, a certain concern and scepticism has risen over the high prices charged by drug companies, their continued problems with productivity, and falling success rates of new drugs. A significant drop in investment in drugmaking companies, and president Obama’s recent reforms of the healthcare system […]


Click here for reuse options!
Copyright 2010 Biotechblog

%d bloggers like this: